BioNTech price target lowered to $132 from $140 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on BioNTech (BNTX) to $132 from $140 and keeps an Overweight rating on the shares. Total Q1 revenue of EUR 183M was “a touch below” consensus of EUR 197M, but BioNTech reiterated 2025 guidance, notes the analyst, who points to lateral Phase 3 data due around mid-year from Summit Therapeutics (SMMT) and Akeso’s HARMONi global study as “the next catalyst for the stock.”